Rocket Lab Poised to Become “Only Viable Alternative” to SpaceX, Says Cantor Fitzgerald
Cantor Fitzgerald reiterated its Overweight rating and $122 price target for Rocket Lab (RKLB), citing Neutron as a potential competitor to SpaceX's Falcon 9. RKLB's backlog surged 137% to $2.4B, and it was named a U.S. Space Force contractor. Q2 FY26 revenue hit $234.07M, up 62% YoY, with a 41.5% gross margin. The stock is down 11.19% in a month but up 42.75% over a year.
How this was made
The 30-second read
Why it matters
Analyst coverage upgrade with a $122 target and highlighted backlog growth could drive buying interest, but execution risk remains.
Market read
The story provides fresh analyst endorsement and contract wins for Rocket Lab, offering a potential catalyst for the stock.
What to watch
Potential cash burn and GAAP losses may limit near‑term upside despite the upgrade.
Background
Rocket Lab (RKLB) is a listed pure‑play launch provider positioning its upcoming Neutron vehicle as a commercial alternative to SpaceX.
Ticker impact
Cantor Fitzgerald reiterated an Overweight rating with a $122 price target and highlighted a 137% backlog surge and new Space Force contract, marking fresh analyst coverage for Rocket Lab.
Potential 10‑15% upside over the next few weeks if the Neutron timeline stays on track.
The upgrade is based on concrete contract wins and a clear growth thesis, but execution risk on Neutron remains.
Market effects
Strengthens the commercial launch services sector by adding a credible second source to SpaceX.
Positive for U.S. aerospace and defense investors, especially those tracking Space Force contracts.
Highlights growing competition in the global small‑sat launch market.
Counterpoint
Execution delays for the Neutron rocket or integration challenges from the Iridium acquisition could stall momentum.
Key entities
- AnalystCantor Fitzgerald
Issued Overweight rating and $122 price target for RKLB.
- GovernmentSpace Force
Named Rocket Lab as an NSSL prime contractor in FY2027 budget.
